amatuximab

Amatuximab (MORab-009) is a humanized chimeric IgG1/k monoclonal antibody targeting cell surface mesothelin (MSLN) with antitumor activity for the treatment of solid tumors.

Anti-Mesothelin Antibody (such as Amatuximab/MORAb-009) is a chimeric monoclonal antibody targeting mesothelin (MSLN). Mesothelin is a glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein that is overexpressed in various malignancies, including mesothelioma, pancreatic cancer, and ovarian cancer, while exhibiting restricted expression in normal tissues. The antibody binds to mesothelin with high affinity, and its mechanisms of action primarily include: 1. Blocking the interaction between mesothelin and MUC16 (CA125), thereby inhibiting tumor cell adhesion and metastasis; 2. Inducing direct tumor cell killing via antibody-dependent cellular cytotoxicity (ADCC). In basic research, it is widely utilized to evaluate the therapeutic efficacy of targeting mesothelin and for the development of antibody-drug conjugates (ADCs).